Earswitch closes seed to validate in-ear sensors for continuous blood pressure monitoring
This article covers Earswitch, a healthtech startup that has closed a seed funding round to advance its EarMetrics in-ear sensing technology for continuous vital sign monitoring. The funding will support product development, clinical validation and commercial readiness for non-invasive in-ear blood pressure and vital sign monitoring aimed at remote patient monitoring, sleep studies and long-term condition management.
Earswitch, a healthtech startup developing in-ear vital sign monitoring, has closed a seed funding round to advance its EarMetrics in-ear sensing technology. The financing will be used for product development, clinical validation and commercial readiness, including work on continuous digital blood pressure monitoring from inside the ear canal — a technique the company says could enable quieter, more continuous monitoring outside clinical settings.
Why it matters
Continuous, non-invasive blood pressure measurement remains a pain point for remote patient monitoring and chronic disease management. Traditional cuff-based devices are episodic and can miss short-term fluctuations that matter for treatment decisions and early warnings. If reliable, in-ear measurement could offer a steady signal source suitable for ambulatory monitoring, sleep studies and long-term condition management, potentially reducing clinic visits and enabling earlier interventions.
Inside the product
Earswitch’s EarMetrics platform is built around sensors placed in the ear canal. The company argues the ear is a stable site close to central arterial signals, which can be favourable for continuous vital sign acquisition. The stated focus is on digital blood pressure monitoring, alongside broader vital sign capture for real-time, unobtrusive measurement.
The business is also participating in the Innovate UK-funded Investor Partnerships - Health Technologies programme in the West Yorkshire ecosystem, a step aimed at clinical validation and preparing the product for commercial trials. Clinical validation is a key hurdle for any medical device seeking NHS adoption or regulatory clearance, and work under the programme should help generate the data required for that path.
Who are the investors?
The round was led by PXN Ventures and included participation from South East Angels, Surrey 100 Angels and Britbots. The syndicate brings a mix of early-stage capital and angel-network support, with investor experience spanning healthcare, robotics and early-stage innovation. The funding is earmarked for advancing development, supporting clinical validation efforts and getting the technology closer to market readiness.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Nick Gompertz, Founder & CEO at Earswitch, said:
We’re delighted to have the backing of such an experienced and aligned group of investors. This funding not only strengthens our ability to bring our technology closer to market, but also validates the enormous potential of in-ear sensing as a new frontier in vital sign monitoring.
The bigger picture
Earswitch’s approach sits within a broader wave of UK healthtech companies pursuing non-invasive, continuous monitoring as remote care and virtual wards scale up. Demonstrating clinical accuracy and securing regulatory approval will determine how quickly such devices are adopted by clinicians and commissioners. Participation in Innovate UK programmes and regional ecosystems like West Yorkshire can help startups bridge early validation to NHS pilot programmes.
The deal also reflects growing interest from UK healthtech investors in sensing and remote-monitoring technologies that promise to integrate with digital care pathways.
This funding round underlines continued public and private support for healthtech innovation in the UK, where clinical partnerships and government-backed validation programmes remain key to taking devices from prototype to patient-facing use across the NHS and European markets.
They've invested in Earswitch
Get to know these healthtech investors
Click here for a full list of 7,589+ startup investors in the UK